28.63 USD
+0.18 (+0.63%)
28.63 USD
0 (0%)
Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 530 industry peers in the Biotechnology industry. ALKS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ALKS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ALKS had positive earnings in the past year.
ALKS had a positive operating cash flow in the past year.
In multiple years ALKS reported negative net income over the last 5 years.
ALKS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 14.57%, ALKS belongs to the best of the industry, outperforming 95.09% of the companies in the same industry.
ALKS has a Return On Equity of 19.58%. This is amongst the best in the industry. ALKS outperforms 96.04% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.22%, ALKS belongs to the top of the industry, outperforming 96.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROIC | 16.22% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 22.30%, ALKS belongs to the top of the industry, outperforming 94.34% of the companies in the same industry.
ALKS has a Operating Margin of 23.59%. This is amongst the best in the industry. ALKS outperforms 95.66% of its industry peers.
ALKS has a Gross Margin of 86.04%. This is amongst the best in the industry. ALKS outperforms 88.68% of its industry peers.
In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALKS is creating value.
The number of shares outstanding for ALKS has been reduced compared to 1 year ago.
The number of shares outstanding for ALKS has been increased compared to 5 years ago.
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ALKS has an Altman-Z score of 6.07. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
ALKS has a better Altman-Z score (6.07) than 74.91% of its industry peers.
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.07 |
ROIC/WACC2.1
WACC7.71%
2.3 Liquidity
A Current Ratio of 3.67 indicates that ALKS has no problem at all paying its short term obligations.
ALKS's Current ratio of 3.67 is in line compared to the rest of the industry. ALKS outperforms 44.53% of its industry peers.
ALKS has a Quick Ratio of 3.27. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
ALKS has a Quick ratio (3.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.71% over the past year.
Measured over the past years, ALKS shows a very strong growth in Earnings Per Share. The EPS has been growing by 32.50% on average per year.
The Revenue has been growing slightly by 1.08% in the past year.
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
3.2 Future
Based on estimates for the next years, ALKS will show a decrease in Earnings Per Share. The EPS will decrease by -1.55% on average per year.
ALKS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.72% yearly.
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.54, the valuation of ALKS can be described as reasonable.
Based on the Price/Earnings ratio, ALKS is valued cheaply inside the industry as 97.17% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ALKS to the average of the S&P500 Index (26.61), we can say ALKS is valued rather cheaply.
A Price/Forward Earnings ratio of 18.80 indicates a rather expensive valuation of ALKS.
ALKS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALKS is cheaper than 94.72% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.01. ALKS is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.54 | ||
| Fwd PE | 18.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaper than 97.55% of the companies in the same industry.
ALKS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALKS is cheaper than 98.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.62 | ||
| EV/EBITDA | 7.94 |
4.3 Compensation for Growth
The decent profitability rating of ALKS may justify a higher PE ratio.
ALKS's earnings are expected to decrease with -19.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.36
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
5. Dividend
5.1 Amount
No dividends for ALKS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.63
+0.18 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change8.97%
Ins Owners1.48%
Ins Owner Change-0.34%
Market Cap4.73B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.87
Price Target44.75 (56.3%)
Short Float %11.63%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)0.32%
PT rev (3m)4.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.27%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)17.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.41%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)3.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.54 | ||
| Fwd PE | 18.8 | ||
| P/S | 3.11 | ||
| P/FCF | 9.62 | ||
| P/OCF | 8.74 | ||
| P/B | 2.73 | ||
| P/tB | 2.87 | ||
| EV/EBITDA | 7.94 |
EPS(TTM)2.48
EY8.66%
EPS(NY)1.52
Fwd EY5.32%
FCF(TTM)2.98
FCFY10.39%
OCF(TTM)3.27
OCFY11.44%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.36
Graham Number24.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROCE | 19.34% | ||
| ROIC | 16.22% | ||
| ROICexc | 40.45% | ||
| ROICexgc | 45.58% | ||
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% | ||
| FCFM | 32.29% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 163.07% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 138.93% | ||
| Profit Quality | 144.77% | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 6.07 |
F-Score6
WACC7.71%
ROIC/WACC2.1
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.04%
EPS Next 2Y-27.54%
EPS Next 3Y-19.2%
EPS Next 5Y-1.55%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.41%
Revenue Next 2Y10.1%
Revenue Next 3Y6.85%
Revenue Next 5Y7.72%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.47%
EBIT Next 3Y5.58%
EBIT Next 5Y14.79%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%
ALKERMES PLC / ALKS FAQ
What is the fundamental rating for ALKS stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALKS.
What is the valuation status for ALKS stock?
ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.
Can you provide the profitability details for ALKERMES PLC?
ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.
What is the valuation of ALKERMES PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ALKERMES PLC (ALKS) is 11.54 and the Price/Book (PB) ratio is 2.73.
What is the expected EPS growth for ALKERMES PLC (ALKS) stock?
The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.04% in the next year.